Collectively, these findings indicate that in vivo targeting of MDM2 by MX69 sensitizes chemo-resistant MM cells to BTZ treatment, induces apoptosis in MM cells and suppresses MM tumor growth. This evidence concerns the gene MDM2 and Miyoshi myopathy.